Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ceapro Inc. stock logo
CRPOF
Ceapro
$0.18
$0.16
$0.11
$0.44
$14.45M1.53500 shsN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
$0.22
$0.22
$0.17
$0.40
$6.47M0.521,730 shsN/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
$13.52
$8.80
$36.88
$8.65M0.83543,436 shs988,300 shs
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
$2.27
+2.3%
$2.18
$1.08
$3.79
$148.59M1.572.42 million shs97,798 shs
ULURU Inc. stock logo
ULUR
ULURU
$0.00
$0.10
$0.79
$5.35M-3.136,691 shsN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ceapro Inc. stock logo
CRPOF
Ceapro
0.00%+4.18%+7.89%+57.56%-56.07%
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
0.00%0.00%-6.36%-12.96%-40.61%
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
0.00%0.00%0.00%0.00%0.00%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-1.77%-5.13%-21.28%+74.80%+63.24%
ULURU Inc. stock logo
ULUR
ULURU
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/AN/AN/AN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
2.4309 of 5 stars
4.42.00.00.02.01.70.0
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
2.80
Moderate Buy$7.25219.38% Upside
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/A

Current Analyst Ratings

Latest NTEC, ULUR, INBP, RGLS, and CRPOF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/25/2024
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
3/19/2024
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
3/18/2024
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/18/2024
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
3/18/2024
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$6.00
3/13/2024
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ceapro Inc. stock logo
CRPOF
Ceapro
$14.49M1.00$0.06 per share2.97$0.32 per share0.58
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
$50.67M0.13$0.04 per share5.75$0.63 per share0.34
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/A$16.18 per shareN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/A$1.05 per shareN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ceapro Inc. stock logo
CRPOF
Ceapro
$3.38M-$0.02N/AN/A-24.95%-8.91%-7.81%5/23/2024 (Estimated)
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
-$30K-$0.01N/AN/A-0.76%-2.05%-1.47%5/6/2024 (Estimated)
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
-$14.13M-$16.32N/AN/AN/AN/A-96.37%-68.87%N/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%5/9/2024 (Estimated)
ULURU Inc. stock logo
ULUR
ULURU
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest NTEC, ULUR, INBP, RGLS, and CRPOF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.40-$0.40N/A-$0.40N/AN/A
2/12/2024Q2 2024
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/A-$0.01-$0.01-$0.01N/A$11.51 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
11.00
7.72
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/A
2.93
0.84
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
N/A
2.34
2.34
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/A
3.31
3.31
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
25.25%
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
22.37%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
92.38%
ULURU Inc. stock logo
ULUR
ULURU
N/A

Insider Ownership

CompanyInsider Ownership
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
45.60%
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
3.30%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
8.41%
ULURU Inc. stock logo
ULUR
ULURU
1.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A78.29 millionN/ANot Optionable
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
14130.10 million16.37 millionNot Optionable
Intec Pharma Ltd stock logo
NTEC
Intec Pharma
40898,000N/AOptionable
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
3065.46 million59.96 millionOptionable
ULURU Inc. stock logo
ULUR
ULURU
230.57 million30.24 millionNot Optionable

NTEC, ULUR, INBP, RGLS, and CRPOF Headlines

SourceHeadline
Better Homes & Gardens: April 26Better Homes & Gardens: April 26
tvtonight.com.au - April 24 at 5:24 AM
AAT Kings extends Australia and New Zealand guided vacations saleAAT Kings extends Australia and New Zealand guided vacations sale
travelweek.ca - April 23 at 2:23 PM
Five great walks in the Northern TerritoryFive great walks in the Northern Territory
australiangeographic.com.au - April 23 at 9:22 AM
What a modern retirement plan should look likeWhat a modern retirement plan should look like
smh.com.au - April 21 at 7:56 AM
Aussies ‘locked out’ of national parks to protect cultural heritageAussies ‘locked out’ of national parks to protect cultural heritage
news.com.au - April 21 at 7:56 AM
The rise of booze-free backpacking: why gen Z are choosing to travel soberThe rise of booze-free backpacking: why gen Z are choosing to travel sober
theguardian.com - April 21 at 7:56 AM
Bolt: Ban on non-Aborigines is the new apartheidBolt: Ban on non-Aborigines is the new apartheid
heraldsun.com.au - April 21 at 7:56 AM
Colin and Joh explore UluruColin and Joh explore Uluru
bhg.com.au - April 19 at 7:00 PM
The 11 Best Road Trips in the WorldThe 11 Best Road Trips in the World
outsideonline.com - April 18 at 4:50 AM
Truth-telling risks inflaming community conflict: reportTruth-telling risks inflaming community conflict: report
afr.com - April 18 at 4:50 AM
It’s political spending that feeds inflation, not Coles and WooliesIt’s political spending that feeds inflation, not Coles and Woolies
afr.com - April 18 at 4:50 AM
Truth, colonisation and Yoorrook: what is Victoria’s truth-telling inquiry and what will it achieve?Truth, colonisation and Yoorrook: what is Victoria’s truth-telling inquiry and what will it achieve?
theguardian.com - April 18 at 4:50 AM
Better Homes & Gardens: April 19Better Homes & Gardens: April 19
tvtonight.com.au - April 17 at 5:32 PM
LET THE GAMES BEGIN! REVERSE: 1999 FIRES OFF AUSTRALIA-THEMED VERSION 1.5 PHASE ONE UPDATE “REVIVAL! THE ULURU GAMES” TODAYLET THE GAMES BEGIN! REVERSE: 1999 FIRES OFF AUSTRALIA-THEMED VERSION 1.5 PHASE ONE UPDATE “REVIVAL! THE ULURU GAMES” TODAY
capsulecomputers.com.au - April 16 at 9:30 PM
Miguel Maestre teams up with Tourism NT and Luxury EscapesMiguel Maestre teams up with Tourism NT and Luxury Escapes
ntnews.com.au - April 15 at 8:22 PM
‘My kids were heartbroken over Bluey’s biggest episode’‘My kids were heartbroken over Bluey’s biggest episode’
adelaidenow.com.au - April 14 at 2:03 PM
The cost of marrying a British princeThe cost of marrying a British prince
msn.com - April 14 at 2:03 PM
Former soldier returns boomerang from nuclear test era to Maralingas traditional ownersFormer soldier returns boomerang from nuclear test era to Maralinga's traditional owners
msn.com - April 14 at 2:03 PM
It’s time to tick Uluru off your family adventure bucket listIt’s time to tick Uluru off your family adventure bucket list
ntnews.com.au - April 12 at 8:48 PM
The Inland Sea: An Australian OdysseyThe Inland Sea: An Australian Odyssey
avclub.com - April 12 at 8:55 AM
There’s nothing to sea here: Cruise dining goes inland for some spectacular new experiencesThere’s nothing to sea here: Cruise dining goes inland for some spectacular new experiences
msn.com - April 12 at 12:54 AM
Host a Screening of Living Black: Never Meant To HappenHost a Screening of Living Black: Never Meant To Happen
sbs.com.au - April 10 at 7:27 AM
Qantas launches surprise 72-hour flight sale to more than 60 domestic destinationsQantas launches surprise 72-hour flight sale to more than 60 domestic destinations
7news.com.au - April 9 at 11:26 AM
How to see the next 20 years of eclipses, including the eclipse of a lifetimeHow to see the next 20 years of eclipses, including the eclipse of a lifetime
msn.com - April 9 at 11:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Ceapro logo

Ceapro

OTCMKTS:CRPOF
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
Integrated BioPharma logo

Integrated BioPharma

OTCMKTS:INBP
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Intec Pharma logo

Intec Pharma

NASDAQ:NTEC
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.
Regulus Therapeutics logo

Regulus Therapeutics

NASDAQ:RGLS
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
ULURU logo

ULURU

OTCMKTS:ULUR
ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.